John Johnson - 05 Jun 2024 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Reporting relationship: Director
Issuer ticker: XERS
Reported as of: 05 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2024, 16:18:54 UTC
Prior SEC filing: 18 Mar 2024
Next SEC filing: 10 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Beth Hecht, as Attorney-in-Fact

Key filing fact

John Johnson filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 05 Jun 2024.

Key facts

This page summarizes John Johnson's Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jun 2024, 16:18.

Change

Previous filing in this sequence was filed on 18 Mar 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XERS transaction

Common Stock

Award

Transaction value: $0
Shares: +50,000
Change %: +5.9%
Price: $0.000000
Shares after: 890,983
Date: 05 Jun 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 5, 2025 or the date of the Company's next annual meeting of stockholders.